Checklist 3: Checklist for discontinuation of guanfacine including monitoring blood pressure and pulse of patients during downward titration

ADHD

This chart is designed to support you in the monitoring of discontinuation and downward titration of Intuniv® ▼ (guanfacine hydrochloride) therapy in paediatric patients with attention-deficit/hyperactivity disorder (ADHD) for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

Patients/caregivers should be instructed not to discontinue guanfacine without consulting their physician. Blood pressure and pulse may increase following discontinuation of Intuniv. In post-marketing experience, hypertensive encephalopathy has been very rarely reported upon abrupt discontinuation of Intuniv. In very rare instances, hypertensive emergencies such as hypertensive encephalopathy have been observed, following abrupt discontinuation.

To minimise the risk of an increase in blood pressure upon discontinuation, the total daily dose of Intuniv should be tapered in decrements of no more than 1mg every 3 to 7 days. Blood pressure and pulse should be monitored when reducing the dose or discontinuing therapy.

It is recommended that this chart be used in conjunction with the Intuniv® SmPC **(click here to view)**.

Please download and print this chart prior to your consultation. It will not be possible for you to store any patient-specific information on the website. The completed chart can be documented within the patient's records.

As you work through the checklist it may also be useful to refer back to the Intuniv® Patient Information Leaflet (PIL) **(click here to view)** with your patient.

	Evaluated
Treatment discontinuation and downward titration	
• Patients/caregivers should be instructed not to discontinue guanfacine without consulting their physician, as this may increase blood pressure and pulse	☐
If treatment is to be discontinued:	
• Dose tapered downward 1mg every 3 to 7 days	☐
• Blood pressure and pulse monitored	☐

Date of initial assessment:	
Patient name:	
Date of birth:	
Age:	Gender:

This chart is intended for use by Healthcare Professionals only, in conjunction with the Intuniv® SmPC
This resource was developed by Takeda as part of a commitment made in the Risk Minimisation Measures for Intuniv®.

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance. Website: www.hpra.ie.
Adverse events should also be reported to Takeda at AE.GBR-IRL@takeda.com.

Version-0015 Date of Approval: July 2022

Takeda

Checklist 3: Checklist for discontinuation of guanfacine including monitoring blood pressure and pulse of patients during downward titration

	Baseline, prior to initiation of downward titration of guanfacine treatment	Subsequent appointments							
Date of assessment									
Dose									
Blood pressure									
Heart rate (pulse) (bpm)									

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

This chart is intended for use by Healthcare Professionals only, in conjunction with the Intuniv® SmPC
This resource was developed by Takeda as part of a commitment made in the Risk Minimisation Measures for Intuniv®.

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance. Website: www.hpra.ie.
Adverse events should also be reported to Takeda at AE.GBR-IRL@takeda.com.

Version-0015 Date of Approval: July 2022

Checklist 3: Checklist for discontinuation of guanfacine including monitoring blood pressure and pulse of patients during downward titration

ADHD

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

	Subsequent appointments							
Date of assessment								
Dose								
Blood pressure								
Heart rate (pulse) (bpm)								

This chart is intended for use by Healthcare Professionals only, in conjunction with the Intuniv® SmPC
This resource was developed by Takeda as part of a commitment made in the Risk Minimisation Measures for Intuniv®.

▼This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance. Website: www.hpra.ie.
Adverse events should also be reported to Takeda at AE.GBR-IRL@takeda.com.

Version-0015 Date of Approval: July 2022

Takeda